Stargardt Disease Implant Lets First Patient Read a Word

A Stargardt disease implant just gave a patient something doctors rarely get to promise: a word on the page. Science Corporation, the neurotech company founded by former Neuralink president Max Hodak, says its first Stargardt patient saw a letter in one rehab session and read a word in the next, according to TechCrunch.

What actually happened

Hodak shared the news on stage at TechCrunch Disrupt in San Francisco. The chip, called PRIMA, went into the patient in May as part of an ongoing trial at Sydney Eye Hospital in Australia. Five months later, the company published a trial update with video of the device being switched on.

The patient first made out a single letter. In the following session, he managed a full word. For someone whose central vision has been fading, that jump from shapes to language is the whole point of the trial.

Why Stargardt disease is such a tough target

Stargardt is an inherited eye disease that gradually destroys central vision. It carves out a blind spot in the middle of what you see, and that spot slowly grows. There is no cure, and the same report says roughly one hundred fifty thousand people worldwide have lost vision to it.

The disease mainly hits the outer retina, where light-sensing cells die. The inner retina, which passes signals to the brain, can stay intact. That matters, because an implant only works if there is still a pathway to plug into.

How the chip works

The procedure takes about an hour. Surgeons place a tiny chip behind the retina, where the natural photoreceptors have degenerated. Patients then wear glasses with a built-in camera that sends the view of the world to the chip, which acts like artificial photoreceptors.

The implant is two millimetres by two millimetres. Hodak was blunt about its limits. "It is not a big field of view color vision," he said, describing a black-and-white patch that is sharp and high-contrast. In his words, it is like looking through a straw, so patients see a couple of letters at a time.

From older adults to a younger group

PRIMA is already sold in Europe for geographic atrophy, an advanced form of age-related macular degeneration. New data presented this week at the American Academy of Ophthalmology meeting showed the gains holding up after three years, according to the American Academy of Ophthalmology. That trial, called PRIMAvera, enrolled thirty-eight patients at seventeen centres across Europe.

The device received its European approval in July. It has not been approved in the United States. Stargardt usually starts in childhood or the teen years, so a working treatment could matter for people far younger than the typical macular degeneration patient.

Why does this matter beyond one clinic? Vision loss tends to strip independence first: reading a menu, spotting a face, checking a phone. Even a narrow window of sharp text can change daily life, which is why researchers care so much about small, early wins like this one. The real test will be how durable the gains are and how many patients benefit once the trial grows.

What comes next

One patient is a milestone, not proof. The company has not released broader results for Stargardt, and a single success story cannot tell us how well the implant works across many people. Treat the headline as an early signal.

Hodak says the next step is a bigger field of view. A larger implant has to deal with the curvature of the eye, and the electrodes need to shrink to get closer to natural levels of detail. He said a next-generation device should be in humans within a year, and that the team expects to get pretty close to native acuity over five years.

There is a bigger story here too. Hodak argues the retina is part of the central nervous system, so retinal implants count as brain-computer interfaces. Science Corporation wants to prove the tech and build a sustainable business first, then push toward other conditions. You can follow more of the science on our science page.

For now, the takeaway is simple and a little emotional. A blind spot that once swallowed text is being pushed back, one letter at a time, by a chip smaller than a postage stamp corner. The straw-sized view is tiny, but for the patient in Sydney it is already a way back to words.